Sandoz acquires GSK antibiotics and Perrigo generics sold to Altaris

Home/Pharma News | Posted 12/03/2021 post-comment0 Post your comment

In February 2021, Sandoz signed an agreement to acquire GSK’s cephalosporin antibiotics business. In March 2021, Perrigo Company sold their generic drug business to private investment firm, Altaris Capital Partners LLC. 

62 MD001919

Sandoz antibiotics acquisition
The Sandoz-GSK agreement includes the global rights to three established antibiotic brands (Zinnat®, Zinacef® and Fortum®) in more than 100 markets. In 2020, it was estimated that the brands had combined sales of approximately US$140 million in the relevant markets.

Sandoz is set to pay GSK US$350 million at closing, which is expected to be in late 2021. There will also be additional milestone payments of up to US$150 million, subject to the terms of the transaction.

The agreement excludes the rights to certain of those brands in the US, Australia and Germany, which were previously divested by GSK. In addition, some rights in India, Pakistan, Egypt, Japan and China, will be retained by GSK.

This comes soon after Sandoz’s 2020 announcement that, together with the Austrian government, there would be investment of more than Euros 150 million in the antibiotic manufacturing site at Kundl in Austria. This is intended to strengthen the long-term competitiveness and supply resilience of antibiotics produced at the facility. This new agreement and long-term plans to manufacture Zinnat® at the Kundl site confirm Sandoz’s commitment to grow their antibiotics business.

Those at Sandoz stated that cephalosporins are the largest antibiotic segment by global sales and acquiring this new business will complement their position at the top of the generic penicillin market.

Altaris generics acquisition
Pharmaceuticals company, Perrigo will be selling its generics business to Altaris for US$1.55 billion. In their press release, Perrigo announced that the sale is part of their transformation plan that hopes to establish Perrigo as a company focusing on quality, affordable self-care medications. Perrigo will now have a portfolio with over US$4 billion in revenues focused on self-managed health and wellness.

Those at Altaris stated that their experience in the pharmaceutical sector will enable them to support the generics business as it becomes a standalone company focused on developing and marketing affordable pharmaceutical products. The sale of this arm of Perrigo’s generics business follows the sale of Rosemont Pharmaceuticals, a UK-based generics producer that Perrigo acquired in 2013 [1].

Related articles
Aurobindo-Sandoz deal falls through biosimilars business transferred to subsidiary

Mylan will not be acquiring Perrigo


To further enhance the objectives of GaBI in sharing information and knowledge that ensure policies supportive of safe biosimilars use, we are pleased to announce that we will be launching a new section on GaBI Online and GaBI Journal, the ‘Latin American Forum’ (in Spanish) featuring the latest news and updates on research and developments in generic and biosimilar medicines in Latin America.

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.



Para fomentar los objetivos de GaBI sobre la difusión de información y conocimiento sobre las políticas de apoyo que garantizan el uso seguro de medicamentos biosimilares, nos complace anunciar el lanzamiento de una nueva sección en GaBI Online y GaBI Journal, el ‘Latin American Forum’ (en español), que presentará las últimas noticias y actualizaciones en investigación y desarrollo sobre medicamentos genéricos y biosimilares en Latinoamérica.

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

1. GaBI Online - Generics and Biosimilars Initiative. Perrigo sells its UK generic drug business []. Mol, Belgium: Pro Pharma Communications International; [cited 2021 Mar 12]. Available from:

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010